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Abstract
Background: Chemoradiotherapy for head and neck cancer (SCCHN) is challenging in elderly, multi-morbid
patients. Radioimmunotherapy (RIT) with cetuximab provides an option to enhance efficacy of radiotherapy
without increased toxicity. We present a single-centre experience of RIT these patients.
Methods: Toxicity and outcome was retrospectively analysed in patients treated with radiotherapy and cetuximab
between 2006 and 2009. Treatment response was analysed at first follow-up, outcome was estimated using Kaplan-
Meier analyses.
Results: 73 patients with primary/recurrent SCCHN were treated (re-irradiation: 22 patients). CTC grade 3 allergic
reactions occurred in 4 patients, grade 3 acneiforme skin reactions leading to discontinuation of cetuximab in 3
patients.
Overall response rate was 59,4%, median locoregional and overall progression-free survival (PFS) was 18 and 15
months, overall survival (OS) 18 months.
Conclusion: RIT is a feasible treatment option for elderly and multi-morbid patients with promising therapeutic
activity. Long-term disease control can also be achieved in patients receiving RIT for re-irradiation.
Background
Concurrent platin-based chemoradiotherapy has long
been established as a standard in definitive treatment of
squamous cell carcinoma of the head and neck
(SCCHN) [1-3]. This applies to nasopharyngeal carci-
noma [4,5], carcinoma of the larynx [6,7] or any other
area of the head and neck [8,9]. Should the patient be
unsuitable to undergo chemoradiotherapy, altered frac-
tionation regimens provide a benefit over standard
radiotherapy alone [10,11] in terms of local control and
also overall survival [11]. However, there is a price to
pay for higher local control rates: platin-containing regi-
mens as well as altered-fractionation RT lead to higher
rates of acute toxicity, i.e. mucositis, grade 3/4
leukopenia and therapy interruptions as compared to
radiotherapy alone [4,6,10-12].
In 2006 though, Bonner and colleagues published
results of combined radioimmunotherapy with the EGF
receptor antibody cetuximab showing improved local
control rates and overall survival without increase of
toxicity or reduction in quality of life [13-15]. This trial
has rapidly caused ample and animated discussions
whether cetuximab should replace standard cisplatin in
the treatment of SCCHN, given the fact, control rates
were similar in retrospective comparisons with radioche-
motherapy trials [16]. In the absence of direct or pro-
spective randomised comparisons between the standard
Cisplatin regimen and cetuximab in concomitant che-
moradiation, guidelines still recommend using standard
regimen for patients fit enough to undergo chemother-
apy [17,18].
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Although in principle, patients should receive curative
therapy regardless of their age [19,20], elderly patients
with SCCHN very often have multiple co-morbidities
and/or poor initial performance status prohibiting inten-
sified treatment schedules.
In accordance with the recommended use of RIT [17]
and in-house standard procedures, these patients are
offered RIT at our institution and have an option for
combined therapy. This is a single centre experience
with RIT using cetuximab for SCCHN from 2006 to
mid-2009.
Methods
Patients receiving radioimmunotherapy with cetuximab
for stage III/IV or recurrent SCCHN between 01/2006
and 06/2009 were identified retrospectively from the
hospital database. Baseline characteristics as well as
treatment parameters were retrieved efficacy and toxicity
of the combination regimen evaluated.
Radiation therapy
RIT
According to our institutional protocols, target volumes
were delineated in accordance with current guidelines
and recommendations [21-23]. Primary RIT is aimed at
delivering doses between 66 - 70 Gy to the primary
tumour/involved nodes or tumour bed and between 54
- 57,6 Gy to the bilateral uninvolved neck.
If IMRT techniques were applied, integrated boost
concepts were preferred applying 2.2 Gy/fraction to
the primary/involved nodes and 1.8 Gy/fraction to the
uninvolved neck. The median dose to the contralateral
parotid gland was below 27 Gy, if possible, also the
ipsilateral parotid gland was spared. The maximum
dose to the spinal cord was limited to below < 40 Gy.
3D-RT usually employed sequential boost concepts at
2 Gy/fraction at similar target doses and organ con-
straints. In 2 D RT (conventional RT) the primary
tumour/involved nodes or tumour bed were aimed at
doses between 60 - 70 Gy, the uninvolved neck
received 50 Gy at 2 Gy/fraction switching to nuchal,
off-cord fields (6 MeV electrons) from 30 Gy. Com-
monly only patients in severely reduced performance
state unable to tolerate longer treatment times were
given conventional treatment; hence no concomitant
boost concept was employed.
RIT as re-irradiation for local relapse
For patients who had already undergone a course of
prior radiotherapy, the treatment volume was strictly
limited to the gross tumour volume and did not include
elective nodal levels. Doses were highly individualised
but aimed at 50 - 60 Gy re-irradiation in 2 Gy/fraction
[24] depending on elapsed time from the first course of
RT and prior RT-dose.
Immunotherapy
After administration of anti-histamines (dimetindene)
and corticosteroids (dexamethasone), cetuximab was
administered as 400 mg/m2 body surface loading dose 7
days prior to RT-treatment start.
Weekly administrations of cetuximab 250 mg/m2
body surface followed for the duration of radiotherapy.
Analysis
Treatment response was analysed 6 weeks post comple-
tion of RIT (first follow-up) according to RECIST cri-
teria [25] based on available follow-up scans (CT or
MRI) and clinical examinations. Treatment outcome
(locoregional, distant and overall progression-free survi-
val as well as overall survival) was evaluated using
higher non-parametric statistics (Kaplan-Meyer survival
analysis [26]/log-rank and Wilcoxon test) with the soft-
ware Xlstat 2010. Progression-free survival was defined
as the time from start of combined radioimmunotherapy
until the first event (i.e. locoregional relapse, distant
metastases, death). Similarly, overall survival was calcu-
lated from start of radioimmunotherapy until death
from any cause. Toxicity was assessed using CTC v 3.0.
Results
Seventy-three patients with SCCHN (median age 69 a
(42 - 86)) were treated with radioimmunotherapy (RIT)
using cetuximab, all of these patients received RIT
instead of chemoradiation due to poor overall perfor-
mance status and multiple co-morbidities (Table 1).
Fifty-one patients received RIT as part of their pri-
mary treatment (group 0) or treatment for local relapse
but did not have prior radiation therapy (group 1).
Twenty-two patients underwent re-irradiation for dis-
ease relapse (group 2), one of these patients continuing
cetuximab for systemic disease management while
undergoing RT for bone metastases, hence this case was
omitted for further analysis. Median follow-up (f/u) was
10.1 months (0.17 - 43.6), 12 patients were lost to f/u,
and 32 patients had deceased as of 05.06.2010 (Table 2).
Patients received a median dose of 66 Gy [16 - 70,6
Gy] for definitive RT (Table 3) and a median dose of 45
Gy [34,2 - 59,6 Gy] for re-irradiation corresponding to a
Table 1 Reasons for RIT





Prior TPF induction 4
Poor performance score (ECOG > 2) 35
Within palliative systemic therapy 2
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median cumulative lifetime dose of 106,4 Gy [96 - 125,6
Gy] (Table 4). The median interval between first and
second course of irradiation was 83,5 months [17 - 293
mo], these patients either had an R2 resection after sal-
vage surgery or were medically unable to have any
major surgical intervention. Most patients were treated
by IMRT (primary RIT: 28/51 pts, re-RT: 16/22 pts).
Patients undergoing 3 D or conventional treatment
could not tolerate longer treatment durations per day
hence were treated with less complex techniques. All of
the patients had marked co-morbidities prohibiting
combined radiochemotherapy and therefore received
combined radioimmunotherapy with cetuximab with a
median of 6 cycles [1-9].
Four patients showed grade 3 allergic reactions to
cetuximab at first exposure leading to discontinuation of
the drug, therefore these patients were not included in
further response/survival analysis. Grade 3 acneiforme
skin reactions were observed in 6 patients (8,3%) and
leading to discontinuation of cetuximab in 3 patients
(4,2%). Five patients (6,9%) had to discontinue RIT due
to deterioration of overall condition (Table 5). Grade 4
or 5 skin reactions were not observed.
Re-RT resulted in 6 cases of grade 3 late toxicity: 4
cases of permanent feeding tube dependency (2 cases
due to oesophageal stenosis/dysphagia, 2 cases due to
silent aspiration). One patient developed painful fibroses
within the re-RT field and one patient developed
Table 2 Baseline characteristics
SCCHN Localisation
laryngeal carcinoma 12 pts
hypopharyngeal carcinoma 6 pts
oropharyngeal carcinoma 21 pts
carcinoma of the oral cavity 19 pts





not available 12 pts
RT available for analysis
primary treatment 51/73 pts 48 pts
re-irradiation 22/73 pts 21 pts
age
median 69 a [42 - 86]
mean 68 a
follow-up (months)
median 10,1 [0,17 - 43,6]
mean 13,8
lost to f/u 12/73 pts
deceased
total 32 pts
primary RT 18 pts
re-RT 14 pts
Table 3 Adverse reactions under RIT (all patients)
°III allergic reaction leading to discontinuation of cetuximab 4 pts
(5,6%)
Skin reactions leading to cetuximab breaks 1 pt
(1,4%)
Skin reactions leading to discontinuation of cetuximab 3 pts
(4,2%)
Overall °III skin reactions 6 pts
(8,3%)




Table 4 Radioimmunotherapy for primary/recurrent











median dose (Gy) 66 [16 - 70,6]
IMRT 28 pts
3D 9 pts
conventional RT 9 pts
RIT
first treatment 38/51 pts
RIT for disease relapse 13/51 pts
> 1 cycle cetuximab 48/51 pts






f/u unavailable 7 pts
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mandibular joint fibrosis necessitating surgical interven-
tion. No patient within the RIT cohort however, has
shown any signs of tissue necrosis, osteoradionecrosis,
or radiogenic vascular haemorrhage (3 patients died of
tumour bleeding due to progressive disease).
According to RECIST, we found an overall response rate
(PR and CR according to RECIST) of 59.4% (41/69 pts),
which was similar both in primary RIT (60,4% (29/48 pts))
and RIT for re-RT 57% (12/21 pts) (Table 3 and 4).
Median locoregional progression-free survival (PFS)
(69 pts) was 17.7 months (mean 25.6 mo, 95% CI: 20.4 -
30.8 mo) while the median distant PFS is not reached
yet (mean 29.6 mo, 95% CI: 25.5 - 33.7 mo). The med-
ian PFS (overall) is 15.1 months (mean 21.3 mo, 95% CI:
16.3 - 26.3 mo) and the median overall survival in this
patient cohort was 15.8 months (mean 23.1 mo, 95% CI:
18.4 - 27.7 mo) (Figure 1, 2, 3, 4).
Subgroup analysis (group 0: primary treatment, group
1: treatment for relapse but no prior RT, group 2: re-
RT) showed significantly lower locoregional and overall
PFS for the two latter groups with median locoregional
PFS not reached for group 0 (mean 31.53 mo, 95% CI:
24.43 - 38.63 mo), group 1 (mean 8.0 mo, 95% CI: 5.4 -
10.7 mo)/group 2 (median locoregional PFS 10.3 mo,
95% CI: 5.6 - 15.1 mo). Similar results were seen for the
median overall PFS (group 0: 20.1 mo, group 1: 8.5 mo,
group 2: 7 mo,). Median OS was also significantly higher
in group 0 (primary treatment) when compared to
group 2 (p = 0.039) (median 25.6 mo vs 8.7 mo in the
re-RT group) (Figure 5, 6, 7, 8).
Whenever possible, patients received IMRT treatment
for their SCCHN, however, in our analysis we did not
observe a significant impact of treatment technique on
locoregional PFS, overall PFS or OS (data not shown).
Discussion
Guidelines recommend application of potentially cura-
tive treatment regimen to patients independent of age
[19,20]. However, special considerations must be made
for elderly patients with co-morbidities associated with a
higher incidence of treatment-related complications.
Our patient cohort consisted of elderly and co-morbid
patients with a median age of 69 years where chemora-
diation was deemed prohibitive and curative surgery was
either not possible due to the patients’ condition or
refused by the patient.
In view of the patients’ poor overall condition at treat-
ment start, aggressive new treatment regimens such as
induction chemotherapy followed by radiation [27,28]
were also no option in this patient cohort. In order to
still offer curative treatment to these patients, radioim-
munotherapy was administered based on the assumption
of lower rate of treatment-related side effects as com-
pared to radiochemotherapy [13,14].
Although the rate of allergic reactions at first exposure
is slightly higher than reported by Bonner and collea-
gues, we found combination treatment with cetuximab
was generally well tolerated leading to a discontinuation
of the medication in only 3 patients. Major acute side-
effects (apart from the 3 allergic reactions) were not
Table 5 Radioimmunotherapy for recurrent SCCHN receiving re-RT
Re-RT (21 pts, 1 pt treated for bone metastases)
IMRT 16/22 pts
3D-RT 3/22 pts
conventional RT 3/22 pts
prior RT Dose (Gy) time between RT treatments (months) cumulative Dose (Gy)
median 66 83,5 106,4
min 40 17 96











f/u unavailable 1 pt
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observed, notably there were no CTC °4/5 acute effects.
Even though, 5 patients did discontinue treatment for
various reasons (3 patients terminating treatment by
their expressed wish, 2 patients due to infections leading
to deterioration of overall condition). However, this did
not seem to be correlated to cetuximab in particular,
rather to underlying initial/pre-therapeutic poor
condition and advanced disease. Overall, the combina-
tion treatment seems feasible in this subset of patients.
The overall remission rate seen in our patients was
59.4% translating into a median PFS of 18 months
(overall) [21 months for patients receiving RIT for pri-
mary treatment, 8.3 and 6.7 months for patients receiv-
ing RIT for locoregional relapse/re-irradiation] and a
Figure 1 Locoregional PFS, all pts (n = 69); Mean 25.6 months, 95% CI: 20.4 - 30.8 months.
Figure 2 Distant PFS, all pts (n = 69); Mean 29.6 months; 95% CI: 25.5 - 33.7 months.
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locoregional PFS of 15 mo (overall) [not reached for pri-
mary treatment/treatment for local relapse; 10 mo for
re-irradiation] respectively. These are somewhat lower
than remission rates and local control found by Bonner
or larger chemoradiotherapy trials [9,29]. However,
about half of our patients had very advanced tumours
(T4: 30 pts) and nodal stages (N2: 31 pts).
Second, we also included patients with locoregional
relapse or multiple relapses of their SCCHN following
initial surgical management as well as patients receiving
re-irradiation for unresectable or only partially resect-
able disease.
Third, all our patients had a very limited to poor pre-
therapeutic performance status and advanced age. As
Figure 3 Overall PFS, n = 69 pts; Mean 21.3 months; 95% CI: 16.3 - 26.3 months.
Figure 4 Overall survival, n = 69 pts; Mean 23.1 months; 95% CI: 18.4 - 27.7 months.
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Figure 5 Locoregional PFS. 0: RIT as primary therapy; mean 31.5 months, 95% CI 24.4 - 38.6 months. 1: RIT for disease relapse; mean 8.0
months; 95% CI 5.4 - 10.7 months. 2: RIT as re-RT; mean 12.8 months; 95% CI 7.6 - 17.9 months. p = 0.009 (0 vs. 1); p = 0.001 (0 vs 2); p = ns (1
vs 2)
Figure 6 Distant PFS. 0: RIT as primary therapy; mean 30.2 months, 95% CI 24.7-35.7 months; 1: RIT for disease relapse; mean 12.5 months; 95%
CI 8.9 - 16.2 months. 2: RIT as re-RT; mean 23.9 months; 95% CI 18.2 - 29.7 months. no statistically significant difference between the groups
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Figure 7 Overall PFS. 0: RIT as primary therapy; mean 24.8 months, 95% CI 19.0-30.6 months 3. 1: RIT for disease relapse; mean 8.7 months; 95%
CI 5.2 - 12.3 months. 2: RIT as re-RT; mean 8.6 months; 95% CI 6.5 - 10.6 months. p = 0.0014 (0 vs 1); p = 0.001 (0 vs 2), p = ns (1 vs 2)
Figure 8 Overall survival. 0: RIT as primary therapy; mean 26.5 months, 95% CI 20.1 - 33.0 months. 1: RIT for disease relapse; mean 14.0
months; 95% CI 9.9 - 18.1 months. 2: RIT as re-RT; mean 12.5 mo; 95% CI 9.2 - 15.7 months. p = 0.039 (0 vs 2), p = ns (0 vs 1 and 1vs 2)
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demonstrated by Cooper et al [30] and more recently by
Agarwal and Siddiqui et al. [31,32] one of the most
important predictive factors for patient outcome are
tumour and nodal stage as well as initial performance
status [33] and also advanced age. Hence, our patients
did in fact show a very negative pre-selection with a
combination of adverse prognostic factors not normally
represented in prospective and/or randomised clinical
trials.
The median overall survival (overall 16 months, group
0 24 months, group 1, group 2 8.7 months) is still
higher than obtained by RT-only in randomised-con-
trolled radiochemotherapy trials [8,9,29,34]. Despite the
higher median age hence a priori lower life expectancy,
the OS is even higher in our patients receiving RIT for
primary treatment (group 0). Median locoregional PFS
with 18 months (overall) is also promising with the
median locoregional PFS above 23 months (group 1)
and 43 months (group 0) and not yet reached to date.
Almost one third of our patients also received RIT for
re-irradiation. While our re-irradiation doses as well as
cumulative lifetime doses were comparatively conserva-
tive [35], treatment response and long-term disease con-
trol is possible also in this subset of patients. Our
response rates compare favourably with response rates
reported by Lee et al [36] and De Crevoisier et al. [37].
Long-term control is possible even though macroscopi-
cally complete surgical salvage in our patients was either
not possible or not attempted at all. Together with
advancing age and multiple recurrences prior to re-RT
been proven negative prognostic factors [36,37]. Re-irra-
diation with high cumulative doses usually comes at the
cost of increased late toxicity. Unfortunately, the follow-
up of this patient subgroup with a median overall survi-
val of 8.7 moths is probably too short to detect further
potential late effects. It should also be mentioned that
only 6 cases of grade 3 therapy-associated late toxicity
were noted (feeding tube dependency: 4 pts, painful
fibroses: 1 pt, mandibular joint fibrosis: 1 pt). Hence the
rate of ≥ grade 3 late toxicity is comparable to late toxi-
city rates reported by Janot et al [24]/Sulman et al [38]
and even lower than reported by Salama et al [35] or
Roh et al. [39]. It is probably noteworthy that IMRT
was used for primary and re-irradiation for maximum
normal tissue sparing whenever tolerable for the patient.
Most of the RT treatments were carried out using
IMRT with only few patients treated with other techni-
ques. A significant influence of RT technique on out-
come could not be shown unlike the findings reported
by of Clavel et al [40].
Conclusion
Results from the RTOG recursive partitioning analysis
[30] as well as Agarwall et al [31] and Yulut-Caloglu et
al [38] suggest initial pre-treatment performance score
as well as advanced age as an independent prognostic
factor in the treatment of head and neck patients. Our
retrospective analysis demonstrates that RIT is a feasible
and well tolerated treatment option in these patients
and that Cetuximab can be safely administered as part
of radioimmunotherapy to patients whose overall perfor-
mance status or co-morbidities do not allow combined
radiochemotherapy. Combination treatment with Cetux-
imab shows promising therapeutic activity with respect
to response rates, local control and overall survival in
the elderly, multi-morbid and extensively pre-treated
patient population. Also, we can support the assumption
that patients treated for local relapse of their disease or
undergoing re-irradiation for recurrent SCCHN show
worse outcomes as compared to the primary situation;
however, local control can still be achieved in this sub-
set of patients.
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